Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (91-100 of 187) with videos related to

Pageof 19
Sort By:
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Leukemia|May 21, 2021
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 1, 2021
Distinct profile of CD34<sup>+</sup> cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive diseaseDorian Forte, Martina Barone, Cristina Morsiani, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Hematological Oncology|May 17, 2017
Comparison of JAK2<sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histologyRoberto Latagliata, Nicola Polverelli, Alessia Tieghi, et al.
The Lancet. Haematology|September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trialClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 11, 2026
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Pageof 19

Showing results (91-100 of 187) with videos related to

Sort By:
Pageof 19
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Leukemia|May 21, 2021
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 studyFrancisco Cervantes, David M Ross, Atanas Radinoff, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 1, 2021
Distinct profile of CD34<sup>+</sup> cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive diseaseDorian Forte, Martina Barone, Cristina Morsiani, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Hematological Oncology|May 17, 2017
Comparison of JAK2<sup>V617F</sup> -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histologyRoberto Latagliata, Nicola Polverelli, Alessia Tieghi, et al.
The Lancet. Haematology|September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trialClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 11, 2026
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1Francesca Palandri, Nicolaas P M Schaap, Jerome Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Pageof 19